Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

2.9K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
2.9K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.1K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
1.1K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

608
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
608

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential regulation of β1-dependent voltage shifts and kinetic modulation by an extracellular glutamate in NaV1.6 VSDIV.

The Journal of general physiology·2026
Same author

Characterization of tryptolinophyllins from the treefrog Boana boans expands the structural and functional diversity of the trypytophyllin family of peptides.

Scientific reports·2026
Same author

Spider venom peptides Ht1a and Gg1a are toxic to honeybee parasite <i>Varroa destructor</i> by topical application.

npj drug discovery·2026
Same author

GPR35 modulates Na<sub>V</sub>1.9 gating and sensory neuron excitability.

British journal of pharmacology·2026
Same author

In vitro bioassays for measuring monoamine transporter function.

Neuropharmacology·2026
Same author

Channeling teamwork: ATP and lipids cooperate to gate P2X receptors.

Science advances·2026

Related Experiment Video

Updated: Jul 23, 2025

Peptide-based Identification of Functional Motifs and their Binding Partners
14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

12.5K

Structure-function relationship of new peptides activating human Nav1.1.

Ludivine Lopez1, Stephan De Waard2, Hervé Meudal3

  • 1Nantes Université, CNRS, INSERM, l'institut du thorax, F-44000 Nantes, France; Smartox Biotechnology, Saint-Egrève, France.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|July 15, 2023
PubMed
Summary

Researchers identified JzTx-34, a peptide that activates the Nav1.1 channel, offering potential for treating neurological and cardiac conditions caused by reduced channel function.

Keywords:
Automated patch clampBiophysicsCellular assayDravet diseaseDrug discoveryHigh-throughput screeningJzTx-34Lead optimizationPeptide synthesisPharmacologyStructural functional relationshipshNa(v)1.1 channel

More Related Videos

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
12:38

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells

Published on: November 6, 2021

2.6K
Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time
08:33

Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time

Published on: March 11, 2021

2.0K

Related Experiment Videos

Last Updated: Jul 23, 2025

Peptide-based Identification of Functional Motifs and their Binding Partners
14:28

Peptide-based Identification of Functional Motifs and their Binding Partners

Published on: June 30, 2013

12.5K
Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells
12:38

Screening Peptides that Activate MRGPRX2 using Engineered HEK Cells

Published on: November 6, 2021

2.6K
Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time
08:33

Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time

Published on: March 11, 2021

2.0K

Area of Science:

  • Pharmacology
  • Neuroscience
  • Molecular Biology

Background:

  • Nav1.1 channels are crucial drug targets for neurological and cardiac disorders.
  • Channel activators are needed to address haploinsufficiency in these conditions.

Purpose of the Study:

  • To discover novel peptide compounds that activate Nav1.1 channels.
  • To investigate the structure-activity relationship of identified peptides to understand their mechanism of action.

Main Methods:

  • Screening of natural peptide sources for ion channel activity.
  • Structure-activity relationship studies of JzTx-34 on Nav1.1.
  • Analysis of structural determinants for peptide synthesis.

Main Results:

  • JzTx-34 was identified as a potent activator of Nav1.1 channels.
  • The pharmacophore of JzTx-34 was elucidated through structure-activity relationship studies.
  • Structural challenges in synthesizing natural ICK peptides targeting Nav1.1 were revealed.

Conclusions:

  • JzTx-34 represents a promising lead compound for Nav1.1-related channelopathies.
  • Understanding the structure-activity relationships facilitates the development of new therapeutic peptides.
  • This research aids in the discovery and development of novel compounds for critical ion channel targets.